ENYO Pharma team will be present in London from the 15th to the 19th of April at the EASL congress on liver diseases.
January 13-16, 2020
San Francisco, USA
“ENYO Pharma team was present at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.”
On the 18th of November, 2019 ENYO Pharma and Edelris inaugurated their new main offices in the Laënnec Bioparc located in Lyon. It was a great moment and we had the honor to host Mr. David Kimelfeld (Metropolis President) and Mr. Michel Le Faou (Municipal Councilor representing the mayor of the 8th arrondissement) for our “biotechnologies and territory development” round table. This new headquarter localization will open promising horizons for collaborations and contribute to ENYO’s growth.
8-12 November, 2019
ENYO Pharma attended the AASLD meeting in Boston and presented four posters as well as performed an oral presentation around FXR agonists in HBV and NASH.
During the conference, ENYO Pharma sponsored a Symposium to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV.
22 October, 2019
ENYO Pharma will participate to the “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” in New York and will present a poste entitled “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”